A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Lymphoma
Interventions
DRUG

SAR245409

Pharmaceutical form:capsule Route of administration: oral

Trial Locations (30)

1000

Investigational Site Number 056003, Brussels

2747

Investigational Site Number 036005, Kingswood

3000

Investigational Site Number 056001, Leuven

3168

Investigational Site Number 036002, Clayton

6000

Investigational Site Number 036003, Perth

7001

Investigational Site Number 036001, Hobart

9000

Investigational Site Number 056002, Ghent

19111

Investigational Site Number 840001, Philadelphia

26506

Investigational Site Number 840002, Morgantown

30912

Investigational Site Number 840006, Augusta

33919

Investigational Site Number 840104, Fort Meyers

34295

Investigational Site Number 250002, Montpellier

35033

Investigational Site Number 250004, Rennes

40536

Investigational Site Number 840013, Lexington

42002

Investigational Site Number 840007, Paducah

44718

Investigational Site Number 840014, Canton

60153

Investigational Site Number 840011, Maywood

60590

Investigational Site Number 276003, Frankfurt am Main

63110

Investigational Site Number 840015, St Louis

69495

Investigational Site Number 250001, Pierre-Bénite

76038

Investigational Site Number 250005, Rouen

89081

Investigational Site Number 276001, Ulm

90033

Investigational Site Number 840012, Los Angeles

94805

Investigational Site Number 250003, Villejuif

66160-7321

Investigational Site Number 840010, Kansas City

02115

Investigational Site Number 840004, Boston

07747

Investigational Site Number 276002, Jena

1105 AZ

Investigational Site Number 528001, Amsterdam

9713 GZ

Investigational Site Number 528003, Groningen

3075 EA

Investigational Site Number 528002, Rotterdam

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT01403636 - A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia | Biotech Hunter | Biotech Hunter